CIK 0001055726
- Non-accelerated filer
- Smaller reporting company
INOVIO PHARMACEUTICALS, INC.
Sign in to watch- Ticker
- INO
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 330969592
- Phone
- +1 858-410-3134
- Business address
- 660 W. GERMANTOWN PIKE, SUITE 110, PLYMOUTH MEETING, PA, 19462
- Former names
- INOVIO BIOMEDICAL CORP, GENETRONICS BIOMEDICAL CORP, GENETRONICS BIOMEDICAL LTD
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2017-05-08 | Kim Jong Joseph Chief Executive Officer | Shares withheld for taxes | −10,755 | $6.29 | $68K | 2,103,875 |
| 2017-05-08 | Kim Jong Joseph Chief Executive Officer | Exercise or conversion · Restricted Stock Unit | −23,333 | 23,333 | ||
| 2017-03-31 | Kim Jong Joseph Chief Executive Officer | Exercise or conversion | +73,590 | $5.08 | $374K | 2,164,887 |
| 2017-03-31 | Kim Jong Joseph Chief Executive Officer | Sale | −73,590 | $6.57 | $484K | 2,091,297 |
| 2017-03-31 | Kim Jong Joseph Chief Executive Officer | Exercise or conversion · Common Stock Option | −73,590 | 0 | ||
| 2017-03-30 | Kim Jong Joseph Chief Executive Officer | Exercise or conversion | +73,590 | $5.08 | $374K | 2,164,887 |
| 2017-03-30 | Kim Jong Joseph Chief Executive Officer | Sale | −73,590 | $6.51 | $479K | 2,091,297 |
| 2017-03-30 | Kim Jong Joseph Chief Executive Officer | Exercise or conversion · Common Stock Option | −73,590 | 73,590 | ||
| 2017-03-27 | COLLINS MORTON Director | Purchase | +21,300 | $6.25 | $133K | 50,000 |
| 2017-03-21 | Bickerstaff George Director | Grant or award · Common Stock Option | +20,000 | $5.86 | $117K | 20,000 |
| 2017-03-21 | Bickerstaff George Director | Grant or award · Restricted Stock Unit | +12,270 | 12,270 | ||
| 2017-03-10 | Sardesai Niranjan Chief Operating Officer | Exercise or conversion | +6,077 | 86,942 | ||
| 2017-03-10 | Sardesai Niranjan Chief Operating Officer | Shares withheld for taxes | −1,859 | $6.68 | $12K | 85,083 |
| 2017-03-10 | Sardesai Niranjan Chief Operating Officer | Grant or award · Common Stock Option | +100,000 | $6.68 | $668K | 100,000 |
| 2017-03-10 | Sardesai Niranjan Chief Operating Officer | Grant or award · Restricted Stock Unit | +61,300 | 61,300 | ||
| 2017-03-10 | Bagarazzi Mark Chief Medical Officer | Grant or award · Common Stock Options | +100,000 | $6.68 | $668K | 100,000 |
| 2017-03-10 | Bagarazzi Mark Chief Medical Officer | Grant or award · Restricted Stock Unit | +61,300 | 61,300 | ||
| 2017-03-10 | Kim Jong Joseph Chief Executive Officer | Exercise or conversion | +139,745 | 2,143,902 | ||
| 2017-03-10 | Kim Jong Joseph Chief Executive Officer | Shares withheld for taxes | −52,605 | $6.68 | $351K | 2,091,297 |
| 2017-03-10 | Kim Jong Joseph Chief Executive Officer | Grant or award · Common Stock Option | +43,150 | $6.68 | $288K | 43,150 |
Page 45 of 49 · 961 trades